Skip to content

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06572215
Acronym
DYNAMO
Enrollment
44
Registered
2024-08-27
Start date
2023-12-14
Completion date
2027-12-31
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Brief summary

This is a feasibility study to assess new, more practical ways of measuring renal reserve.

Detailed description

Quantification of glomerular filtration rate (GFR) over time is the standard assessment of kidney function. In clinical practice, the endogenous marker, 'serum creatinine' concentration, is used as a static assessment of kidney function to estimate GFR. However, serum creatinine fails to increase until at least 50% of kidney tissue is lost,\[2\] thus is an inadequate indicator of early CKD. GFR like many other physiological processes is not static and augments temporarily to stimuli such as exercise and protein intake, by up to 25% from baseline in healthy individuals.\[3\] Similar to cardiac function stress tests which predict adverse outcomes, inability to respond to renal stressors or 'reduced renal reserve' has been demonstrated to occur prior to development of CKD (e.g. in patients with diabetes and previous acute kidney injury (AKI)) and is associated with vulnerability to future AKI, despite the presence of apparently normal kidney function measured by serum creatinine concentration.\[4\] Renal reserve is lost with progressive CKD,\[4\] and has also been demonstrated to relate to severity of histological lesions.\[5\] Current measurements of renal reserve (stimulated increase in GFR due to augmented renal blood flow above basal fasting values) involve administration of a compound that is freely filtered by the glomerulus, unaffected by tubular function and is physiologically inert, with assessment before and after an oral protein load or amino acid infusion which induces arterial vasodilation, increasing renal blood flow and GFR The study proposes a comparison of two novel methods of 'dynamic renal function testing' with renal reserve testing.

Interventions

DRUGDapagliflozin

On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.

Sponsors

King's College Hospital NHS Trust
Lead SponsorOTHER
King's College London
CollaboratorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Inclusion: * Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml/min/1.73m2 OR * Previous living kidney donation * Age ≥ 4No contraindication or known allergy to any trial medications. * Willing and able to provide written informed consent Exclusion: * Aged \< 40 * Unable or unwilling to provide informed consent * Breastfeeding or pregnant women * Patients involved in other interventional research studies.

Design outcomes

Primary

MeasureTime frame
Change in eGFR from baseline to 2hours after oral protein load2 hours

Countries

United Kingdom

Contacts

CONTACTKate Bramham, Doctor
kch-tr.research@nhs.net0203 299 9000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026